CNR1 and Alzheimer disease: The case of cannabinoid receptors (CB1 and CB2) has gained much attention as potential pharmacotherapeutic targets to control some CNS disorders, in particular those related to neuroinflammatory and neurodegenerative events, such as Alzheimer’s disease (AD) [24,25].